- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Skye Bioscience Inc (SKYE)
Track today's live Skye Bioscience (SKYE) share price, performance and key data on this page with our current NASDAQ:SKYE stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Skye Bioscience share price on the NASDAQ exchange. Use the dropdown to switch exchange for the SKYE share price, head to our technical summary section, which provides analysis on Skye Bioscience share price buy/sell indicators using real-time data (or discuss the Skye Bioscience (SKYE) stock price today with other investors in the Skye Bioscience NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:SKYE share price (ISIN: US83086J3095) to enhance your trading decisions with our free investment tools and resources.
What Is the Skye Bioscience Inc Share Price Today?
The Skye Bioscience share price today is 1.8000.
What Is the Stock Symbol for Skye Bioscience Inc
The stock symbol (or 'ticker') for Skye Bioscience Inc is "SKYE."
What Stock Exchange Does Skye Bioscience Inc Trade On?
Skye Bioscience Inc is listed and trades on the NASDAQ stock exchange.
Is Skye Bioscience Inc a Good Stock to Buy?
Determining whether Skye Bioscience (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:SKYE share price (ISIN: US83086J3095) to enhance your trading decisions with our free investment tools and resources.
What Is the Skye Bioscience Inc Share Price Today?
The Skye Bioscience share price today is 1.8000.
What Is the Stock Symbol for Skye Bioscience Inc
The stock symbol (or 'ticker') for Skye Bioscience Inc is "SKYE."
What Stock Exchange Does Skye Bioscience Inc Trade On?
Skye Bioscience Inc is listed and trades on the NASDAQ stock exchange.
Is Skye Bioscience Inc a Good Stock to Buy?
Determining whether Skye Bioscience (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
1.8000
0.0000(0.00%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.6400
1.8100
52 wk Range
1.6400
39.9216
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.64001.8100
52 wk Range
1.640039.9216
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SKYE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
60.8000
Upside
+3,277.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Skye Bioscience to acquire Redx Pharma in $125M deal- Investing.com
Form 8K Skye Bioscience Inc For: 19 August- Investing.com
- Form 8K Skye Bioscience Inc For: 14 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 60.8000
(+3,277.78% Upside)
Skye Bioscience Inc SWOT Analysis
Nimacimab's Promise | Skye Bioscience's lead candidate for obesity treatment shows potential for efficacy without neuropsychiatric side effects, addressing a critical market need |
Financial Runway | With $59.2 million in cash, Skye is funded through Q1 2027, providing ample time for key clinical milestones and potential strategic developments |
Market Opportunity | Explore how Skye's novel approach to obesity treatment could capture a significant share of a growing market, potentially attracting big pharma interest |
Analyst Optimism | Learn about the bullish outlook from analysts, with price targets ranging from $14 to $15, reflecting confidence in Skye's innovative obesity treatment approach |
Skye Bioscience Inc Earnings Call Summary for Q4/2025
- Skye Bioscience ended 2025 with $25.7M in cash, extending operational runway through Q4 2026 via disciplined capital allocation.
- CBeyond trial demonstrated significant weight loss when nimacimab combined with semaglutide, targeting second-line obesity treatment market.
- Company advancing Antibody-Peptide Conjugate program alongside CB1 antibody nimacimab to simplify dosing regimens for obesity therapy.
- Four analysts revised earnings upward; InvestingPro rates financial health 'GREAT' at 3.65 despite pre-revenue clinical-stage status.
- Key risks include FDA regulatory hurdles for combination therapies, funding constraints, and competition from established GLP-1 treatments.
Last Updated: 10/03/2026, 21:36
Read Full TranscriptEarnings
Latest Release
14/08/2026
EPS / Forecast
-2.16 / -1.98
Revenue / Forecast
-- / --
Compare SKYE to Peers and Sector
Metrics to compare | SKYE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSKYEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −1.1x | −0.4x | |
PEG Ratio | 0.01 | −0.42 | 0.00 | |
Price/Book | −16.0x | 2.8x | 2.6x | |
Price / LTM Sales | - | 172.6x | 3.1x | |
Upside (Analyst Target) | - | 694.1% | 49.0% | |
Fair Value Upside | Unlock | 2.2% | 7.0% | Unlock |
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Skye Bioscience (NASDAQ: SKYE) Share Price Today?
The Skye Bioscience stock price today is 1.8000 USD.
What Stock Exchange Does Skye Bioscience (SKYE) Trade On?
Skye Bioscience is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Skye Bioscience?
The stock symbol (also called a 'ticker') for Skye Bioscience is "SKYE."
What Is the Current Skye Bioscience Market Capitalisation?
As of today, Skye Bioscience (NASDAQ: SKYE) market cap is 50.5100M USD.
What Is Skye Bioscience's (SKYE) Earnings Per Share (TTM)?
The Skye Bioscience EPS is currently -10.2399 (Trailing Twelve Months).
When Is the Next Skye Bioscience Earnings Date?
Skye Bioscience's next earnings report will be released on 05/11/2026.
Is SKYE a Buy or Sell From a Technical Analyst Perspective?
Based on today's Skye Bioscience moving averages and other technical indicators, the daily buy/sell signal for SKYE stock is Strong Sell.
How Many Times Has Skye Bioscience Stock Split?
Skye Bioscience has split 3 times. (See the SKYE stock split history page for full effective split date and price information.)
What is the current trading status of Skye Bioscience (NASDAQ: SKYE)?
As of 02/09/2026, Skye Bioscience (SKYE) is trading at a share price of 1.8000 USD, with a previous close of 2.5500 USD. The stock has fluctuated within a day range of 1.6400 USD to 1.8100 USD, while its 52-week range spans from 1.6400 USD to 39.9216 USD.
What Is Skye Bioscience (SKYE) Price Target According to Analysts?
The average 12-month price target for Skye Bioscience is 60.8000 USD, with a high estimate of 160 USD and a low estimate of 16 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +3,277.78% Upside potential.
What Is the SKYE After Hours Price?
SKYE's last after hours stock price is 1.8100 USD, the stock has decreased by 0.0100, or 0.5600%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.